Pharvaris N.V. (PHVS) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Perrigo (PRGO) over the past year, gaining 36.2% versus a loss of 30.1%. Over five years, PHVS leads with a +96.8% price change compared with -66.3% for PRGO. Pharvaris N.V. is the larger company by market cap ($2.18 billion vs $2.08 billion), about 1.0 times the size.
Perrigo pays a dividend yielding 7.70%, while Pharvaris N.V. does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | PRGO |
|---|---|---|
| Share price | $31.10 | $15.06 |
| Market cap | $2.18B | $2.08B |
| 1-day change | -0.06% | +3.86% |
| YTD return | +12.07% | +8.19% |
| 1-year return | +36.16% | -30.12% |
| 5-year return | +96.84% | -66.32% |
| Forward P/E | — | 6.28 |
| EPS (TTM) | $-3.06 | $-12.28 |
| Dividend yield | 0.00% | 7.70% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | — | $4.25B |
| Revenue growth (YoY) | — | -2.75% |
| Net income (latest FY) | $-25.99M | $-1.43B |
| Gross margin | — | 35.14% |
| Operating margin | — | -26.39% |
| Net margin | — | -33.51% |
| 52-week high | $43.25 | $22.02 |
| 52-week low | $20.65 | $9.23 |
| Distance from 52-week high | -28.09% | -31.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +84.47% | +9.56% |
| Average volume | 711.75K | 2.79M |
| Shares outstanding | 70.20M | 138.37M |
| Employees | 148 | 8,100 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed PRGO by 66.3 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.70% vs 0.00%).
- The two companies sit in different sectors: Pharvaris N.V. in Healthcare and Perrigo in Health Care.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Healthcare · Biotechnology · 148 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
PHVS vs PRGO FAQ
Which is bigger, Pharvaris N.V. or Perrigo?
Pharvaris N.V. (PHVS) is larger, with a market capitalization of $2.18B compared with $2.08B for Perrigo (PRGO).
Which stock has performed better over the past year, PHVS or PRGO?
PHVS returned +36.16% over the past 12 months, compared with -30.12% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Pharvaris N.V. or Perrigo?
Perrigo pays a dividend yielding 7.70%, while Pharvaris N.V. does not currently pay a regular dividend.
Are Pharvaris N.V. and Perrigo in the same industry?
No. Pharvaris N.V. is in the Healthcare sector, while Perrigo is in Health Care.